PARP1 and cancer: Olaparib was the first PARP inhibitor approved by the FDA [42] (December 2014) for cancer therapy, and PARP-1 inhibitors have been identified and tested after clinical trials and their function in enhancing the response of cancers to radiation has been documented [15,43].